Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

@article{Smith2012RituximabFR,
  title={Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.},
  author={Rona M. Smith and Rachel Bronwen Jones and Mary-Jane Guerry and Simona Laurino and Fausta Catapano and Afzal N. Chaudhry and Kenneth G C Smith and David R. W. Jayne},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 11},
  pages={3760-9}
}
OBJECTIVE Rituximab is effective induction therapy in refractory or relapsing antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, further relapse is common, and maintenance strategies are required. The aim of this study was to reduce relapse rates using a fixed-interval rituximab re-treatment protocol. METHODS Retrospective, standardized collection of data from sequential patients receiving rituximab for refractory or relapsing AAV at a single center was studied. Group A… CONTINUE READING